中国临床药理学杂志2018，Vol.34Issue(9)：1035-1038,4.DOI:10.13699/j.cnki.1001-6821.2018.09.008
埃克替尼片治疗ⅢA-N2期非小细胞肺癌的临床研究
Clinical trial of icotinib tablets in the treatment of stage ⅢA-N2 non-small cell lung cancer
摘要
Abstract
Objective To observe the clinical efficacy and safety of icotinib tablets in the treatment of stage Ⅲ A-N2 non-small cell lung cancer (NSCLC).Methods A total of 56 patients with stage ⅢA-N2 NSCLC were randomly divided into control group and treatment group with 28 cases per group.The control group was treated with 60-75 mg · m-2 docetaxel,once a week,intravenous drip,or 500 mg · m pemetrexed,once every 3 weeks,intravenous drip,discontinuation of treatment when the disease progresses or adverse drug reactions cannot be tolerated.The treatment group was treated with icotinib tablets 125 mg,tid,orally,discontinuation of treatment when the disease progresses or adverse drug reactions cannot be tolerated.The clinical efficacy,peripheral blood dendritic cell subsets,and adverse drug reactions were compared between two groups.Results After treatment,the objective remission rates of the treatment group and the control group were 89.29％ (25 cases/28 cases) and 71.43％ (22 cases/28 cases),the difference was statistically significant (P ＜ 0.05).After treatment,the number of dendritic cells (DC) in the treatment group and the control group were (15.44 ± 2.08) and (12.83 ± 1.71) × 106/L,the ratio of dendritic cells to mononuclear cells (DC/PBMC) were (0.62 ± 0.08) ％ and (0.57 ± 0.07) ％,the differences were statistically significant (P ＜ 0.05).The adverse drug reactions of two groups were rashes,diarrhea and mild liver dysfunction.The total incidences of adverse drug reactions in the treatment group and the control group were 46.43％ and 42.86％ without significant difference (P ＞ 0.05).Conclusion The clinical efficacy of icotinib tablets in the treatment of stage ⅢA-N2 NSCLC was exact,and it did not increase the incidence of adverse drug reactions.关键词
埃克替尼片/ⅢA-N2期非小细胞肺癌/安全性Key words
icotinib tablet/stage ⅢA-N2 non-small cell lung cancer/safety分类
医药卫生引用本文复制引用
王建国,王淑仙,田梦园,王岩,阮宇向,黄胜楠..埃克替尼片治疗ⅢA-N2期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2018,34(9):1035-1038,4.基金项目
国家自然科学基金资助项目(81272444) （81272444）
